Spinal Cord Injury Neuroprotection With Glyburide

Exclusion Criteria

• •1. Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours
• •2. Acute SCI with ASIA Impairment Scale grade D or E
• •3. Currently involved in another non-observational SCI research study or receiving another investigational drug
• •4. History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components
• •5. Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation (at discretion of the site investigator)
• •6. Unable to commit to the follow-up schedule
• •7. A recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study
• •8. Any condition likely to result in the patient's death within the next 12 months
• •9. Prisoner
• •10. Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of \< 30 mL/min/1.73 m2
• •11. Known severe liver disease, or ALT \> 3 times upper limit of normal or bilirubin \> 2 times upper limit normal. Subjects may be randomized if liver function tests have been drawn but are not yet available and the subject has no known history of liver disease; however, treatment with DiaBeta will be discontinued prior to the second dose if liver function tests indicate ALT \> 3 times upper limit of normal or bilirubin \> 2 times upper limit of normal
• •12. Blood glucose \<55 mg/dL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia
• •13. Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or QTc \> 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months
• •14. Known treatment with Bosentan within past 7 days
• •15. Known G6PD enzyme deficiency
• •16. Pregnancy: Women must be either post-menopausal, permanently sterilized or, if ≤ 50 years old, must have a negative test for pregnancy obtained before enrollment
• •17. Breast-feeding women who do not agree to stop breast-feeding during and for 7 days following the end of oral glyburide administration
• •18. Subjects who in the opinion of the investigator are not suitable for inclusion in the study (reason to be documented).